As reported on BioSpace, the U.S. Food and Drug Administration has approved Regeneronโs Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic
Historic Milestone Offers Relief from Relentless Burden of Glycogen Storage Disease Type Ia According to a recent press release from Ultragenyx, after decades of medical
As reported by allsci, Chinaโs National Medical Products Administration (NMPA) has granted conditional approval to TransThera Sciencesโ Yochanra (tinengotinib) for adults with unresectable, advanced, or
As reported by PharmaBiz, Zydus Lifesciences has announced the launch of Revahale (revefenacin), a once-daily nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of
What Happened? Hansa Biopharma, a Swedish company, announced that the first patient in Australia has successfully received a kidney transplant after being treated with a
As reported on BioSpace, AstraZeneca has discontinued a pivotal Phase 3 trial evaluating its investigational bispecific antibody volrustomig in advanced non-small cell lung cancer (NSCLC)
New observational research suggests that addressing obesity alongside inflammatory joint disease could improve treatment outcomes for people with psoriatic arthritis (PsA). As reported on MedIndia,
As reported on News Medical, researchers are highlighting a new class of therapies that could improve outcomes for people living with primary biliary cholangitis (PBC),
Researchers at MIT have identified a potential new approach to reducing lung cancer risk by targeting caspase-1, an enzyme involved in inflammation. Findings published in
A recent study shared by The Lancet shows that a first-in-class investigational therapy targeting neurotrophin-3 (NT-3) significantly reduced pain and improved function in patients with
As reported by the ICIJ, the FDA originally approved Keytruda (pembrolizumab) combined with cisplatin and gemcitabine on October 31, 2023, to treat locally advanced inoperable
Editor’s Note: Patient Worthy is honored to present this article, originally written by Camille Johnson. People living with chronic illness or long-term treatment plans often
Editor’s Note: Patient Worthy is honored to share this article with you, kindly provided to us by our friends at End Sepsis. To see the
If you had asked me a few years ago what I thought my biggest health concern would be, lung cancer wouldn’t have even crossed my
Some battles arenโt visible to the people around us.
Living with a chronic or rare condition can mean fighting for your health every single dayโmanaging symptoms, making appointments, advocating for answers, navigating treatments, and simply finding the energy to keep going.
Resting isnโt laziness. Slowing down isnโt giving up. And needing support doesnโt make you weak.
Youโre fighting a battle many people may never fully understand. And that takes strength.
#PatientWorthy #ChronicIllness #RareDisease #InvisibleIllness #PatientAdvocacy #ChronicIllnessAwareness #Quote #MotivationalQuote #InspirationalQuote #PatientWorthy
This week, Patient Worthy is focusing on non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, highlighting the latest information, patient experiences, and advancements shaping this community.
Throughout the week, we'll explore topics including diagnosis, biomarker testing, treatment options, emerging research, and the real-life experiences of those living with KRAS G12C-positive NSCLC. Our goal is to provide education, inspiration, and support while helping raise awareness of this unique form of lung cancer.
Whether you're a patient, care partner, advocate, or healthcare professional, we invite you to join us as we share stories, resources, and insights that empower the NSCLC community. Interested in sharing your own journey? click the link below to learn more.
ow.ly/C7xz50ZNuHU
#FocusOfTheWeek #NSCLC #KRASG12C #LungCancer #lungcancerawareness #PatientWorthy #PatientStories #cancercommunity
Children's Craniofacial Association๐๐๐ ๐๐๐ ๐๐๐๐ช?โฃโฃ
#FacialPalsy
๐๐ข๐ฑ๐ฑ๐บ #cam2026, ๐ต๐ข๐จ ๐ถ๐ด ๐ช๐ฏ ๐บ๐ฐ๐ถ๐ณ ๐ค๐ฆ๐ญ๐ฆ๐ฃ๐ณ๐ข๐ต๐ช๐ฐ๐ฏ๐ด ๐ข๐ฏ๐ฅ ๐ด๐ต๐ฐ๐ณ๐ช๐ฆ๐ด ๐ต๐ฉ๐ช๐ด ๐ฎ๐ฐ๐ฏ๐ต๐ฉ! #๐๐๐๐๐ช๐ฅ๐ดโฃโฃ #CamReflect
โฃโฃ-โโฃ
โฃ
๐ฅ๏ธ ow.ly/wEoz50WOUKOโฃ
๐ ๐
๐๐๐๐๐จ๐จ๐ค: / ccakidsโฃ
๐ ๐๐ง๐ฌ๐ญ๐๐ ๐ซ๐๐ฆ: @ccakidsโฃ
๐ง [email protected]โฃ
DONATE AT:โฃ
โช ow.ly/wEoz50WOUKOโฃ
โช ๐๐๐ฒ๐๐๐ฅ: [email protected]โฃ
โช ๐๐๐ฅ๐ฅ๐: [email protected]โฃ
[Image Description: Yellow graphic with a white border and an orange title text that reads: "Facial Palsy" with black text below in an orange background that reads "causes complete or partial paralysis of the facial motion. The act of facial motion starts in the brain and travels through the facial nerves to the muscles in the face. These muscles then contract in response to a stimulus" The Bottom Left Corner has a CAM logo]
#apertsyndrome #crouzonsyndrome #pfeiffersyndrome #facialpalsy #facialparalysis #hemifacialmicrosomia #goldenharsyndrome #nagersyndrome #craniosynostosis #Hemangioma #CraniodiaphysealDysplasia #Craniodiaphyseal #Dysplasia #treachercollins #carpentersyndrome #coffinlowrysyndrome #antleybixlersyndrome #millersyndrome #neurofibromatosis #moebiussyndrome #pierrerobinsequence #fibrousdysplasia #microtia
ยฉ Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
